Here, we report that intratumoral MMR therapy in a mouse model of HCC not only suppressed tumor growth and extended survival but also synergized with anti-PD-1 and anti-CTLA-4 blockade to remodel the protumorigenic TME. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.